[go: up one dir, main page]

WO2003000114A3 - Utilisation du monoxyde de carbone pour ameliorer des resultats dans des transplantations de tissus et d'organes et supprimer l'apoptose - Google Patents

Utilisation du monoxyde de carbone pour ameliorer des resultats dans des transplantations de tissus et d'organes et supprimer l'apoptose Download PDF

Info

Publication number
WO2003000114A3
WO2003000114A3 PCT/US2002/019687 US0219687W WO03000114A3 WO 2003000114 A3 WO2003000114 A3 WO 2003000114A3 US 0219687 W US0219687 W US 0219687W WO 03000114 A3 WO03000114 A3 WO 03000114A3
Authority
WO
WIPO (PCT)
Prior art keywords
carbon monoxide
tissue
organ transplants
suppresses apoptosis
improves outcomes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/019687
Other languages
English (en)
Other versions
WO2003000114A2 (fr
WO2003000114A9 (fr
Inventor
Fritz H Bach
Edda M Tobiasch
Miguel C Soares
Leo E Otterbein
Jeanne GOSE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Beth Israel Deaconess Medical Center Inc
Original Assignee
Yale University
Beth Israel Deaconess Medical Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27404726&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2003000114(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to KR1020097018077A priority Critical patent/KR20090110362A/ko
Priority to JP2003506568A priority patent/JP4521183B2/ja
Priority to KR10-2003-7016702A priority patent/KR20040032115A/ko
Priority to BR0210599-3A priority patent/BR0210599A/pt
Priority to CA002451266A priority patent/CA2451266A1/fr
Priority to SI200230772T priority patent/SI1404811T1/sl
Priority to HK04107560.1A priority patent/HK1067380B/en
Priority to EP02747932A priority patent/EP1404811B1/fr
Priority to HU0400371A priority patent/HUP0400371A3/hu
Priority to SK1594-2003A priority patent/SK15942003A3/sk
Priority to DK02747932T priority patent/DK1404811T3/da
Priority to MXPA03012031A priority patent/MXPA03012031A/es
Application filed by Yale University, Beth Israel Deaconess Medical Center Inc filed Critical Yale University
Priority to AU2002318377A priority patent/AU2002318377B2/en
Priority to DE60229848T priority patent/DE60229848D1/de
Publication of WO2003000114A2 publication Critical patent/WO2003000114A2/fr
Publication of WO2003000114A3 publication Critical patent/WO2003000114A3/fr
Priority to NO20035637A priority patent/NO20035637L/no
Anticipated expiration legal-status Critical
Publication of WO2003000114A9 publication Critical patent/WO2003000114A9/fr
Priority to AU2008221551A priority patent/AU2008221551A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Transplantation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention se rapporte à des méthodes de transplantation d'organes, de tissus et de cellules individuelles. L'invention se rapporte également à des méthodes permettant de maintenir des cellules in vitro et d'accroître la survie et/ou la fonction des cellules après la transplantation. Les méthodes consistent en l'administration de monoxyde de carbone en une dose suffisante pour accroître la survie et/ou la fonction des cellules.
PCT/US2002/019687 2001-06-21 2002-06-21 Utilisation du monoxyde de carbone pour ameliorer des resultats dans des transplantations de tissus et d'organes et supprimer l'apoptose Ceased WO2003000114A2 (fr)

Priority Applications (16)

Application Number Priority Date Filing Date Title
DE60229848T DE60229848D1 (de) 2001-06-21 2002-06-21 - und organtransplantationen und unterdrückt apoptose
DK02747932T DK1404811T3 (da) 2001-06-21 2002-06-21 Carbonmonoxid forbedrer resultater i vævs- og organtransplantationer og undertrykker apoptose
KR10-2003-7016702A KR20040032115A (ko) 2001-06-21 2002-06-21 조직 및 장기 이식 결과의 개선 및 아폽토시스의 억제에사용되는 일산화탄소
BR0210599-3A BR0210599A (pt) 2001-06-21 2002-06-21 Uso de monóxido de carbono, método para manutenção de uma célula animal in vitro, artigo de manufatura, bem como meio celular estéril
CA002451266A CA2451266A1 (fr) 2001-06-21 2002-06-21 Utilisation du monoxyde de carbone pour ameliorer des resultats dans des transplantations de tissus et d'organes et supprimer l'apoptose
SI200230772T SI1404811T1 (sl) 2001-06-21 2002-06-21 Ogljikov monoksid izboljša rezultate pri presaditvi tkiva in organov ter prepreči apoptozo
HK04107560.1A HK1067380B (en) 2001-06-21 2002-06-21 Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis
EP02747932A EP1404811B1 (fr) 2001-06-21 2002-06-21 Le monoxyde de carbone ameliore les resultats dans des transplantations de tissus et d'organes et supprime l'apoptose
HU0400371A HUP0400371A3 (en) 2001-06-21 2002-06-21 Use of carbon monoxide for preparation of pharmaceutical composition available for improving survival or function of organ following transplantation
KR1020097018077A KR20090110362A (ko) 2001-06-21 2002-06-21 조직 및 장기 이식 결과의 개선 및 아폽토시스의 억제에 사용되는 일산화탄소
MXPA03012031A MXPA03012031A (es) 2001-06-21 2002-06-21 El monoxido de carbono mejoraresultados en transplantes de tejido y organo y suprime apoptosis.
JP2003506568A JP4521183B2 (ja) 2001-06-21 2002-06-21 組織および臓器移植の転帰を改善しかつアポトーシスを抑制する一酸化炭素
SK1594-2003A SK15942003A3 (sk) 2001-06-21 2002-06-21 Farmaceutická kompozícia s obsahom oxidu uhoľnatého zlepšujúca prežívanie alebo funkciu orgánov po transplantácii
AU2002318377A AU2002318377B2 (en) 2001-06-21 2002-06-21 Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis
NO20035637A NO20035637L (no) 2001-06-21 2003-12-17 Karbonmonoksyd forbedrer resultatene av vev og organ transplantater og undertrykker apoptose
AU2008221551A AU2008221551A1 (en) 2001-06-21 2008-09-18 Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US30028901P 2001-06-21 2001-06-21
US60/300,289 2001-06-21
US33434001P 2001-11-29 2001-11-29
US60/334,340 2001-11-29
US33797401P 2001-12-07 2001-12-07
US60/337,974 2001-12-07

Publications (3)

Publication Number Publication Date
WO2003000114A2 WO2003000114A2 (fr) 2003-01-03
WO2003000114A3 true WO2003000114A3 (fr) 2003-04-10
WO2003000114A9 WO2003000114A9 (fr) 2004-05-21

Family

ID=27404726

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/019687 Ceased WO2003000114A2 (fr) 2001-06-21 2002-06-21 Utilisation du monoxyde de carbone pour ameliorer des resultats dans des transplantations de tissus et d'organes et supprimer l'apoptose

Country Status (25)

Country Link
US (2) US7238469B2 (fr)
EP (2) EP1404811B1 (fr)
JP (1) JP4521183B2 (fr)
KR (1) KR20040032115A (fr)
CN (1) CN100502650C (fr)
AT (1) ATE413883T1 (fr)
AU (2) AU2002318377B2 (fr)
BG (1) BG108492A (fr)
BR (1) BR0210599A (fr)
CA (1) CA2451266A1 (fr)
CY (1) CY1108798T1 (fr)
CZ (1) CZ20033448A3 (fr)
DE (1) DE60229848D1 (fr)
DK (1) DK1404811T3 (fr)
ES (1) ES2316583T3 (fr)
HU (1) HUP0400371A3 (fr)
MX (1) MXPA03012031A (fr)
NO (1) NO20035637L (fr)
NZ (1) NZ562962A (fr)
PL (1) PL367544A1 (fr)
PT (1) PT1404811E (fr)
SG (1) SG147305A1 (fr)
SI (1) SI1404811T1 (fr)
SK (1) SK15942003A3 (fr)
WO (1) WO2003000114A2 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8128963B2 (en) * 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
US7678390B2 (en) * 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
GB0111872D0 (en) * 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
BR0210599A (pt) 2001-06-21 2004-07-20 Beth Israel Hospital Uso de monóxido de carbono, método para manutenção de uma célula animal in vitro, artigo de manufatura, bem como meio celular estéril
US20080026984A1 (en) * 2002-02-04 2008-01-31 Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
US7968605B2 (en) * 2002-02-04 2011-06-28 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
AU2003208525B9 (en) 2002-02-04 2009-08-27 Alfama-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda Amend the invention title to read Method for treating a mammal by administration of a compound having the ability to release CO, compounds having the ability to release CO and pharmaceutical compositions thereof
UA86344C2 (ru) 2002-02-13 2009-04-27 Бет Ізрейел Діконісс Медікал Сентер, Інк. Способ лечения сосудистых заболеваний
RS91004A (sr) 2002-04-15 2007-02-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education, Postupci za lečenje ileusa
HRP20040973A2 (en) * 2002-04-15 2005-06-30 University Of Pittsburgh Of The Commonwealth Syste Method of treating necrotizing enterocolitis
JP2005522521A (ja) * 2002-04-15 2005-07-28 ベス イスラエル デアコネス メディカル センター ヘムオキシゲナーゼ−１およびヘム分解産物の使用法
RS99304A (sr) 2002-05-17 2007-04-10 Yale University, Postupci za lečenje hepatitisa
CN1674922A (zh) * 2002-06-05 2005-09-28 耶鲁大学 治疗血管生成、肿瘤生长以及转移的方法
PL375161A1 (en) * 2002-06-21 2005-11-28 University Of Pittsburgh Of The Commonwealth System Of Higher Education Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation
HRP20050389A2 (en) * 2002-11-07 2005-08-31 University Of Pittsburgh Of The Commonwealth Systeyale University Treatment for hemorrhagic shock
GB2395432B (en) * 2002-11-20 2005-09-14 Northwick Park Inst For Medica Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs
CN1901795B (zh) * 2003-10-22 2014-03-26 弗雷德哈钦森癌症研究中心 用于在细胞，组织，器官，和有机体中诱导停滞的方法，组合物和装置
EP1552840A1 (fr) * 2004-01-07 2005-07-13 Aga Ab Mélange de xénon et de monoxyde de carbone pour la protection de cellules
WO2006096774A2 (fr) 2005-03-07 2006-09-14 Sangart, Inc. Composition et methodes de diffusion de monoxyde de carbone (co) et de monoxyde d'azote (no) dans un tissu en utilisant des proteines heme comme supports
EP1937059A2 (fr) 2005-07-27 2008-07-02 University Of North Carolina At Charlotte Composition et procede pour la restauration et la preservation d'organes de transplantation provenant de donneurs par donation suite a une mort cardiaque
US20070207993A1 (en) * 2005-12-20 2007-09-06 Alfama - Investigacao E Desenvolvimetno De Productos Farmaceuticos Lda Molybdenum carbonyl complexes for treating rheumatoid arthritis and other inflammatory diseases
WO2007073226A1 (fr) * 2005-12-20 2007-06-28 Alfama - Investigação E Desenvolvimento De Produtos Farmacêuticos Lda Procede de traitement d'un mammifere par l'administration d'un compose capable de liberer du co
GB0601394D0 (en) 2006-01-24 2006-03-01 Hemocorm Ltd Therapeutic delivery of carbon monoxide
EP2099463B1 (fr) 2006-11-07 2014-07-16 The General Hospital Corporation Atténuation de la vasoconstriction induite par un transporteur d'oxygène vasoactif
HRP20171020T1 (hr) 2009-05-27 2017-10-06 Ino Therapeutics Llc Uređaj za aktivranje indeksiranog ventila i sklop spremnika pod tlakom s ovratnikom
AU2009202685B1 (en) 2009-06-30 2010-08-19 Ino Therapeutics Llc Methods of treating term and near-term neonates having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension
EP3583851A1 (fr) 2011-01-14 2019-12-25 Children's Hospital Los Angeles Solution de monoxyde de carbone utilisable en vue du traitement d'une maladie, notamment la drépanocytose
US8927750B2 (en) 2011-02-04 2015-01-06 Universitaet Zu Koeln Acyloxy- and phosphoryloxy-butadiene-Fe(CO)3 complexes as enzyme-triggered co-releasing molecules
BR112013023740A2 (pt) 2011-03-16 2016-08-02 Dynasil Biomedical Corp métodos e materiais para prolongamento da armazenagem útil de preparações de glóbulo vermelho e preparações de plaqueta
JP5978291B2 (ja) 2011-04-19 2016-08-24 アルファーマ インコーポレイテッドＡｌｆａｍａ，Ｉｎｃ． 一酸化炭素放出分子およびその使用
WO2012170843A1 (fr) * 2011-06-10 2012-12-13 Geno Llc Récipient pressurisé d'oxyde nitrique (no)
WO2013013179A1 (fr) 2011-07-21 2013-01-24 Alfama, Inc. Molécules libérant du ruthénium-monoxyde de carbone et utilisations de celles-ci
US9987302B2 (en) 2011-08-09 2018-06-05 Beth Israel Deaconess Medical Center, Inc. Methods of treating DNA damage
US9629358B2 (en) 2013-03-15 2017-04-25 Mallinckrodt Hospital Products IP Limited Administration and monitoring of nitric oxide in ex vivo fluids
ES2981406T3 (es) 2013-03-15 2024-10-08 Mallinckrodt Pharmaceuticals Ireland Ltd Administración y monitorización de óxido nítrico en fluidos ex vivo
TW201618795A (zh) 2014-04-15 2016-06-01 波泰里斯股份有限公司 用以改良器官功能及延長器官移植物壽命之系統及方法
US10842812B2 (en) 2015-08-12 2020-11-24 The General Hospital Corporation Compositions and methods that promote hypoxia or the hypoxia response for treatment and prevention of mitochondrial dysfunction and oxidative stress disorders
CN105288599A (zh) * 2015-10-22 2016-02-03 徐州医学院 血红素氧化酶-2在制备抑制器官移植免疫排斥制剂中的应用
MX2020001853A (es) * 2017-08-25 2020-08-03 Mallinckrodt Hospital Products Ip Ltd Métodos para mejorar la viabilidad de los órganos.
EP3524290A1 (fr) 2018-02-09 2019-08-14 Julius-Maximilians-Universitaet Wuerzburg Procédé et système de surveillance de monoxyde de carbone (co) pour administrer des fluides ex vivo
CN116076484A (zh) * 2022-11-30 2023-05-09 武汉大学 一种修复肾脏损伤的低温携氧机械灌注液及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4264739A (en) * 1979-01-05 1981-04-28 Merck & Co., Inc. Sparger for cell culture system
US4923817A (en) * 1987-11-23 1990-05-08 "Immuno" Aktiengesellschaft Fur Chemisch-Medizinische Fermenter for culturing cell cultures
US5240912A (en) * 1983-05-09 1993-08-31 Todaro George J Transforming growth factor (TGF) peptides

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4053590A (en) 1975-02-27 1977-10-11 Alza Corporation Compositions of matter comprising macromolecular hemoglobin
JPS5679957A (en) 1979-12-05 1981-06-30 Sogo Seibutsu Igaku Kenkyusho:Kk Erucinia enterocolitica polysaccharide sensitizing blood cell and method of detecting erucinia enterocolitica polysaccharide antibody using this
US5084380A (en) 1985-01-29 1992-01-28 Applied Biotechnology Monoclonal antibodies reactive with activated and oncogenic ras p21 proteins
CN85202057U (zh) * 1985-05-31 1986-09-10 南京低压阀门厂 电热丝预热凹槽式燃油系统
US5449665A (en) 1985-09-24 1995-09-12 Item Development Aktiebolag Continuous intravenous infusion of adenosine to human patients undergoing percutaneous transluminal angioplasty
DE3928144A1 (de) * 1989-08-25 1991-02-28 Hoechst Ag Zyklische pyridin-2,4- und -2,5-dicarbonsaeurediamide, verfahren zu deren herstellung sowie deren verwendung
US5180366A (en) 1990-10-10 1993-01-19 Woods W T Apparatus and method for angioplasty and for preventing re-stenosis
US5792325A (en) 1990-11-15 1998-08-11 Richardson, Jr.; William H. Electric arc material processing system
US5570683A (en) 1990-12-05 1996-11-05 The General Hospital Corporation Methods and devices for treating pulmonary vasoconstriction and asthma
US5396882A (en) 1992-03-11 1995-03-14 The General Hospital Corporation Generation of nitric oxide from air for medical uses
US5293875A (en) 1992-06-16 1994-03-15 Natus Medical Incorporated In-vivo measurement of end-tidal carbon monoxide concentration apparatus and methods
DE69433723T3 (de) * 1993-02-22 2008-10-30 Abraxis Bioscience, Inc., Los Angeles Verfahren für die in-vivo-verabreichung von biologischen substanzen und hierfür verwendbare zusammensetzungen
EP0804244A1 (fr) * 1993-03-26 1997-11-05 Biorelease Technologies, Inc. Compositions comportant des proteines heminiques et methodes associees
US5763431A (en) 1993-08-20 1998-06-09 Jackson; Meyer B. Method for regulating neuropeptide hormone secretion
DE4421433C1 (de) 1994-06-18 1995-06-08 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Wirkstoffen, die Kohlenmonoxid-Quellen darstellen, Verfahren zu seiner Herstellung und seine Verwendung
US5476764A (en) 1994-09-16 1995-12-19 The Regents Of The University Of California Method using CO for extending the useful shelf-life of refrigerated red blood cells
US6066333A (en) 1994-09-22 2000-05-23 William Harvey Research Limited Pharmaceutical control of inflammation
US5664563A (en) 1994-12-09 1997-09-09 Cardiopulmonary Corporation Pneumatic system
US5914316A (en) 1994-12-16 1999-06-22 Washington University Method of inhibiting intimal hyperplasia
US6063407A (en) 1995-02-16 2000-05-16 The General Hospital Corporation Treatment of vascular thrombosis and restenosis with inhaled nitric oxide
US5712293A (en) 1995-06-07 1998-01-27 Sepracor, Inc. Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
FR2735382B1 (fr) * 1995-06-15 1997-07-25 Air Liquide Installation de production de monoxyde de carbone incorporant une unite de separation cryogenique
ES2217313T3 (es) 1995-06-30 2004-11-01 Zymogenetics, Inc. Bencenosulfonamidas o sulfonilureas de 4-(2-(n-(-2-carboxamidoindol)aminoetilo) como antagonistas del pdfg.
EP0914103B1 (fr) 1996-04-05 2006-06-28 The General Hospital Corporation Traitement d'un type d'hemoglobinose
US6069132A (en) 1996-08-14 2000-05-30 Revanker; Ganapathi R. Phosphazole compounds
DK0921807T3 (da) 1996-08-27 2004-03-15 Messer Griesheim Gmbh Hydrogenholdigt lægemiddel
US6315995B1 (en) 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
ATE358492T1 (de) * 1996-09-27 2007-04-15 Univ Columbia Behandlung einer ischämischen störung und zur verbesserung des infarktergebnis
US8128963B2 (en) * 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
US6316403B1 (en) 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
US5869538A (en) * 1996-11-26 1999-02-09 Research Foundation Of State University Of New York Method for enhancing transport of gases to tissues
FR2757259B1 (fr) * 1996-12-18 1999-03-05 Valeo Thermique Moteur Sa Ailette metallique perfectionnee pour echangeur de chaleur, notamment pour vehicule automobile
US5912019A (en) * 1997-02-07 1999-06-15 Musc Foundation For Research Development Compounds for reducing ischemia/reperfusion injury
JP4695259B2 (ja) 1998-03-16 2011-06-08 セルジーン コーポレイション ２−（２，６−ジオキソピペリジン−３−イル）イソインドリン誘導体、その製剤および炎症性サイトカイン阻害剤としてのその使用
US6203991B1 (en) 1998-08-21 2001-03-20 The Regents Of The University Of Michigan Inhibition of smooth muscle cell migration by heme oxygenase I
US7678390B2 (en) * 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
US20050250688A1 (en) 1999-04-01 2005-11-10 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
US7632803B2 (en) * 1999-10-01 2009-12-15 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
US6558825B1 (en) * 2000-05-12 2003-05-06 Reveo, Inc. Fuel containment and recycling system
FR2812197B1 (fr) 2000-07-27 2003-01-03 Air Liquide Sante Int Utilisation de co dans le traitement de l'inflammation des voies aeriennes superieures ou des bronches
FR2816212A1 (fr) 2000-11-03 2002-05-10 Air Liquide Sante Int Utilisation de monoxyde de carbone (co) dans le traitement des inflammations du systeme cardiovasculaire
WO2002080859A2 (fr) 2001-03-20 2002-10-17 Glaxo Group Limited Associations de medicaments administrees par inhalation
CN1507348A (zh) * 2001-03-30 2004-06-23 ɣ����ҽҩ��˾ 用于治疗血管性、炎性和免疫疾病的一氧化碳生成性组合物
GB0111872D0 (en) * 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
WO2002096387A1 (fr) 2001-05-25 2002-12-05 Medtronic, Inc. Dispositif medical implantable equipe d'un systeme de liberation controlee d'agents gazeux
BR0210599A (pt) * 2001-06-21 2004-07-20 Beth Israel Hospital Uso de monóxido de carbono, método para manutenção de uma célula animal in vitro, artigo de manufatura, bem como meio celular estéril
AU2003208525B9 (en) 2002-02-04 2009-08-27 Alfama-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda Amend the invention title to read Method for treating a mammal by administration of a compound having the ability to release CO, compounds having the ability to release CO and pharmaceutical compositions thereof
UA86344C2 (ru) * 2002-02-13 2009-04-27 Бет Ізрейел Діконісс Медікал Сентер, Інк. Способ лечения сосудистых заболеваний
JP2005522521A (ja) * 2002-04-15 2005-07-28 ベス イスラエル デアコネス メディカル センター ヘムオキシゲナーゼ−１およびヘム分解産物の使用法
HRP20040973A2 (en) * 2002-04-15 2005-06-30 University Of Pittsburgh Of The Commonwealth Syste Method of treating necrotizing enterocolitis
RS91004A (sr) * 2002-04-15 2007-02-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education, Postupci za lečenje ileusa
RS99304A (sr) * 2002-05-17 2007-04-10 Yale University, Postupci za lečenje hepatitisa
CN1674922A (zh) * 2002-06-05 2005-09-28 耶鲁大学 治疗血管生成、肿瘤生长以及转移的方法
PL375161A1 (en) * 2002-06-21 2005-11-28 University Of Pittsburgh Of The Commonwealth System Of Higher Education Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation
HRP20050389A2 (en) * 2002-11-07 2005-08-31 University Of Pittsburgh Of The Commonwealth Systeyale University Treatment for hemorrhagic shock
US20050255178A1 (en) * 2004-02-04 2005-11-17 Bloch Kenneth D Enhancing the effectiveness of an inhaled therapeutic gas

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4264739A (en) * 1979-01-05 1981-04-28 Merck & Co., Inc. Sparger for cell culture system
US5240912A (en) * 1983-05-09 1993-08-31 Todaro George J Transforming growth factor (TGF) peptides
US4923817A (en) * 1987-11-23 1990-05-08 "Immuno" Aktiengesellschaft Fur Chemisch-Medizinische Fermenter for culturing cell cultures

Also Published As

Publication number Publication date
AU2002318377B2 (en) 2008-06-19
US7238469B2 (en) 2007-07-03
HUP0400371A3 (en) 2010-06-28
EP2033514A2 (fr) 2009-03-11
NO20035637D0 (no) 2003-12-17
JP2005500875A (ja) 2005-01-13
CY1108798T1 (el) 2014-04-09
BR0210599A (pt) 2004-07-20
EP1404811A4 (fr) 2006-08-09
MXPA03012031A (es) 2005-07-01
JP4521183B2 (ja) 2010-08-11
SI1404811T1 (sl) 2009-04-30
PT1404811E (pt) 2009-01-22
PL367544A1 (en) 2005-02-21
ATE413883T1 (de) 2008-11-15
WO2003000114A2 (fr) 2003-01-03
EP2033514A3 (fr) 2009-04-29
NZ562962A (en) 2009-08-28
SK15942003A3 (sk) 2004-08-03
ES2316583T3 (es) 2009-04-16
KR20040032115A (ko) 2004-04-14
EP1404811A2 (fr) 2004-04-07
NO20035637L (no) 2004-02-17
DE60229848D1 (de) 2008-12-24
US20030039638A1 (en) 2003-02-27
SG147305A1 (en) 2008-11-28
HUP0400371A2 (hu) 2004-08-30
BG108492A (bg) 2005-02-28
CZ20033448A3 (cs) 2004-05-12
HK1067380A1 (en) 2005-04-08
US20070202083A1 (en) 2007-08-30
CA2451266A1 (fr) 2003-01-03
DK1404811T3 (da) 2009-03-02
AU2008221551A1 (en) 2008-10-09
CN1545548A (zh) 2004-11-10
WO2003000114A9 (fr) 2004-05-21
EP1404811B1 (fr) 2008-11-12
CN100502650C (zh) 2009-06-24

Similar Documents

Publication Publication Date Title
WO2003000114A3 (fr) Utilisation du monoxyde de carbone pour ameliorer des resultats dans des transplantations de tissus et d'organes et supprimer l'apoptose
WO2004101758A3 (fr) Composition pouvant maintenir la viabilite d'organes et de cellules
WO2004009767A3 (fr) Therapie cellulaire de regeneration
MXPA02007137A (es) Fuente de tejido hepatico.
WO2004113513A3 (fr) Procedes et compositions pour moduler la croissance et la differentiation des cellules souches
WO2007035843A3 (fr) Procédés et compositions pour fonctionnalité d'organes et de tissus
WO2003077864A3 (fr) Procedes et compositions pour diriger des cellules vers des organes cibles
WO2009045360A3 (fr) Elimination des tumeurs au moyen d'un perfusat placentaire humain et de cellules tueuses naturelles intermediaires provenant d'un placenta humain
AU2003273276A1 (en) Methods and compositions for the preservation of cells, tissues or organs in the vitreous state
WO2003012060A3 (fr) Compositions cellulaires facilitant le greffage des cellules souches hematopoietiques et minimisant le risque de gvhd
WO2004039248A3 (fr) Reparation ou remplacement de tissus ou d'organes
EP1676574A3 (fr) Procédé favorisant la survie des tissus ou cellules griffées
WO2007025215A3 (fr) Perfusion mecanique de greffons tissulaires a transplanter
AU2002331356A1 (en) Nanoparticles for dna administration to a target organ
WO2002098361A3 (fr) Reparation et regeneration de tissus induites par des cellules t
WO2007139939A3 (fr) Méthodes et compositions faisant appel à des composés immunomodulateurs utilisés en traitement combiné
EP2216033A3 (fr) Méthode de traitement d'une maladie par transplantation d'organes ou de tissus allogenes or xenogenes
WO2005047469A3 (fr) Proteine isogloboside 3 synthase porcine, adnc, organisation genomique, et region regulatrice
WO2001040444A3 (fr) Procede et compositions pour preparer des transplants cellulaires
WO2003102162A3 (fr) Nouvelles cellules dendritiques tolerogeniques et utilisations therapeutiques de celles-ci
IL190289A0 (en) Method for obtaining human smooth muscular cells and uses thereof
WO2005055877A3 (fr) Procede de fabrication de transplants de cellules discales et utilisation en tant que materiau de transplantation
WO2003029432A3 (fr) Cellule souche mesenchymateuse humaine
GB2379446A (en) Cells,culture methods and their uses
EP1728857A3 (fr) Mise à disposition de tissu hépatique.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US UZ VN YU ZA ZW

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002318377

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2163/DELNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: PV2003-3448

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 200309828

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 15942003

Country of ref document: SK

Ref document number: PA/a/2003/012031

Country of ref document: MX

Ref document number: 2451266

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020037016702

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 10849202

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2002747932

Country of ref document: EP

Ref document number: 1-2003-501340

Country of ref document: PH

Ref document number: 2003506568

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 530671

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 20028163443

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2002747932

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2003-3448

Country of ref document: CZ

COP Corrected version of pamphlet

Free format text: PAGES 1/12-12/12, DRAWINGS, REPLACED BY NEW PAGES 1/10-10/10; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWE Wipo information: entry into national phase

Ref document number: 1020097018077

Country of ref document: KR